How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,058 results for

Speech Language Pathology

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Radiation therapy for oropharyngeal squamous cell carcinoma: executive summary of an ASTRO evidence-based clinical practice guideline.

KQ2H : Post-operative chemotherapy should not be delivered alone or sequentially with PORT. Recommendation strength: Strong Quality of evidence: High In the scenario of intermediate-risk pathologic factors such as lymphovascular invasion (LVI), perineural invasion (PNI), T3-4 disease, or positive lymph nodes? Statement KQ2I : Patients with intermediate-risk factors should not routinely receive concurrent systemic therapy with PORT. Recommendation strength: Strong Quality of evidence: Moderate (...) Statement KQ2J : Patients with intermediate-risk factors whose surgical procedure and/or pathologic findings imply a particularly significant risk of locoregional recurrence may receive concurrent cisplatin-based chemotherapy after a careful discussion of patient preferences and the limited evidence supporting its use in this scenario; alternative systemic treatment regimens should only be used in the context of a clinical trial. Recommendation strength: Conditional Quality of evidence: Low Statement

2017 National Guideline Clearinghouse (partial archive)

202. Parkinson's disease in adults.

professional should spend more time considering and discussing the options with the patient. A National Institute for Health and Care Excellence (NICE) pathway titled "Parkinson's disease overview" is provided on the . Parkinson's disease Diagnosis Evaluation Management Treatment Geriatrics Neurological Surgery Neurology Nursing Physical Medicine and Rehabilitation Psychiatry Speech-Language Pathology Advanced Practice Nurses Allied Health Personnel Health Care Providers Hospitals Nurses Occupational (...) if non-pharmacological management (for example, speech and language therapy; see "Speech and Language Therapy" below) is not available or has not been effective. [2017] Consider glycopyrronium bromide 9 to manage drooling of saliva in people with Parkinson's disease. [2017] If treatment for drooling of saliva with glycopyrronium bromide 9 is not effective, not tolerated or contraindicated (for example, in people with cognitive impairment, hallucinations or delusions, or a history of adverse effects

2017 National Guideline Clearinghouse (partial archive)

203. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease&mdash

2015. The December 2006 date provided the recommended 1-year overlap with the end of the previous search. The search yield was also supplemented by articles provided by the Work Group members through February 2017. The search strategy included Medical Subject Headings (MeSH) and text terms for chronic kidney disease (CKD) and the interventions and markers of interest (see Supplementary Appendix A [see the "Availability of Companion Documents" field]) and was limited to the English language. The ERT (...) , pediatric, and transplant nephrology, endocrinology, cardiology, bone histomorphometry pathology, and epidemiology attended the conference. Four topic areas were considered: (i) vascular calcification; (ii) bone quality; (iii) calcium and phosphate; and (iv) vitamin D and parathyroid hormone (PTH). Each participant was assigned to 1 of the 4 topics based on their area of expertise. Participants identified new studies in their topic area and answered a set of questions to determine which recommendations

2017 National Guideline Clearinghouse (partial archive)

204. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline.

. Inclusion and Exclusion Criteria Non-English-language studies were excluded Inclusion Criteria for KQ1 Designs Randomized controlled studies (RCTs), except that RCTs that assigned treatments based on pathological staging were excluded Non-RCT if: Comparative Concurrent Multicenter ≥500 patients Some method to control for selection bias (propensity scores, instrumental variables, multivariate regression) For effectiveness: Either the Surveillance, Epidemiology, and End Results (SEER) program

2017 National Guideline Clearinghouse (partial archive)

205. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology.

institution with expertise in the management of acute leukemia for treatment, the initial institution should, whenever possible, defer invasive procedures, including bone marrow aspiration and biopsies, to the treatment center to avoid duplicate procedures, associated patient discomfort, and additional costs ( Strong recommendation ). If a patient is referred to another institution for treatment, the primary institution should provide the treatment center with all laboratory results, pathology slides (...) Diagnosis Evaluation Hematology Oncology Pathology Clinical Laboratory Personnel Physician Assistants Physicians To recommend laboratory testing for the initial workup for proper diagnosis, determination of prognostic factors, and possible future monitoring of acute leukemias (ALs), including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and ALs of ambiguous lineage, in children and adults To answer the following key questions: What clinical and laboratory information should

2017 National Guideline Clearinghouse (partial archive)

206. VA/DoD clinical practice guideline for diagnosis and treatment of low back pain.

neurologic deficits (e.g., radiculopathy, neurogenic claudication), red flag symptoms associated with serious underlying pathology (e.g., malignancy, fracture, infection), and psychosocial factors. ( Strong For; Reviewed, Amended ) For patients with low back pain, the Work Group suggests performing a mental health screening as part of the low back pain evaluation and taking results into consideration during selection of treatment. ( Weak For; Reviewed, New-replaced ) For patients with acute axial low

2017 National Guideline Clearinghouse (partial archive)

207. Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate: a guideline.

in the electronic database MEDLINE through PubMed on March 3, 2016. No limit or filter was used for the time period covered or English language, but articles were subsequently culled for English language. A combination of the following medical subject headings or text words were used: abortion; ART; assisted reproductive techn*; birth; embolization; embolization/therapeutic; embryo transfer; endoscopic; endoscopy; fertility; fertilization in vitro; fibroid; fibroma; fibromyoma; hysteroscopy; intrauterine (...) ; intrauterine insemination; intrauterine pathology; intrauterine pathologies; in vitro fertilization; in vitro fertilisation; IUI; IVF; laparoscopic; laparoscopy; laparotomy; leiomyoma; metroplast*; miscarriage; myoma; myomect*; pregnancy; pregnancy outcome; removal; reproductive techniques, assisted; uterine; uterine myomectomy; uterine neoplasms; uterus. Initially, titles and abstracts of potentially relevant articles were screened and reviewed to develop inclusion/exclusion criteria (see Table 1

2017 National Guideline Clearinghouse (partial archive)

208. Clinical practice guideline: evaluation of the neck mass in adults.

Profile Quality improvement opportunity: Avoid unnecessary open biopsy with its associated complications and promote timely FNA as the initial pathologic test for a patient with a neck mass at increased risk of malignancy (National Quality Strategy domains: safety, effective treatment) Aggregate evidence quality: Grade A, systematic reviews with a consistent reference standard Level of confidence in evidence: High Benefits: Rapid, cost-effective test with high sensitivity and specificity for diagnosis (...) document. The English-language searches were performed in multiple databases, including PubMed (MEDLINE), EMBASE, CINAHL, Cochrane Library, National Guideline Clearinghouse, National Institute for Health and Care Excellence (NICE) UK, and Canadian Medical Association (CMA) Infobase (Canada). In certain instances, targeted searches for lower-level evidence were performed to address gaps from the systematic searches identified in writing the guideline from April 2016 through November 2016. January 1980

2017 National Guideline Clearinghouse (partial archive)

209. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: a report of the American Dental Association.

, and their use should be considered only in the context of research. Low Conditional * Clinician refers to the target audience for this guideline, but only those trained to perform biopsies (that is, dentists) should do so. † Examination refers to initial, routine, or emergency visits. ‡ Symptoms could include globus sensation, unexplained ear or oropharyngeal pain, and hoarseness. § Specialist refers to clinicians with advanced training in oral and maxillofacial surgery, oral and maxillofacial pathology (...) malignant disorders in the oral cavity" is provided in the . Potentially malignant disorders (PMDs) and oral squamous cell carcinomas (OSCCs) Note : Sarcomas or carcinomas of the lips, oropharynx, and salivary glands are not within the scope of this guideline. Diagnosis Evaluation Screening Dentistry Oncology Otolaryngology Pathology Advanced Practice Nurses Allied Health Personnel Dentists Nurses Physician Assistants Physicians To provide clinicians with updated evidence-based recommendations

2017 National Guideline Clearinghouse (partial archive)

210. Chronic pain disorder medical treatment guideline.

of chronic low back pain with disc pathology, a high degree of anxiety or depressive symptomatology is associated with relatively less pain relief in spite of higher opioid dosage than when these symptoms are absent (Design: Prospective cohort study ). Evidence Statements Regarding Opioids and Adverse Events Good Evidence In generally healthy patients with chronic musculoskeletal pain, treatment with long-acting opioids, compared to treatments with anticonvulsants or antidepressants, is associated

2017 National Guideline Clearinghouse (partial archive)

211. ACR/ASNR/SIR/SNIS Practice Parameter for the Performance of Endovascular Embolectomy and Revascularization in Acute Stroke

the usefulness/effectiveness is considered uncertain or less well established by evidence or opinion. A Class 3 recommendation represents a course of action for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective, and in some cases may be harmful [15,16]. CNS infarction – CNS infarction is brain, spinal cord, or retinal cell death attributable to ischemia, based on pathological, imaging, other objective evidence of cerebral, spinal cord, or retinal focal (...) or symptoms 1 = Grade 1: No significant disability; able to carry out all the usual activities of daily living without assistance. NOTE: This does not preclude the presence of weakness, sensory loss, language disturbance, etc, but implies that these are mild and do not or have not caused patient to limit his/her activities (eg, if employed before, is still employed at the same job). 2 = Grade 2: Slight disability; unable to carry out some previous activities but able to look after own affairs without much

2018 Society of Interventional Radiology

212. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 with the exception that the SUV max is used in the United States as the quantitative measurement

]. Directcommunication Abnormalities of immediate clinical importance should be directly or verbally communicated to the appropriate health- careproviderifadelayintreatmentmightresultinsignificant morbidity. An example of such an abnormality would be a lesionwithahighriskofpathologicalfracture.Otherclinical- ly significant unexpected findings should also be communi- cated verbally. Reporting of abnormalities requiring urgent attention should be consistent with the policy (...) on large patient body habitus when the quality of the study is affected. & Description of the location, the extent and the intensity (SUV and/or SUL) of pathological FDG accumulation relatedtonormaltissue. & Description ofrelevant findingson CTand their relation- shiptopathologicalFDGaccumulation.FDGuptakemay bereportedasmild,moderateorintenseandcomparedto the background uptake in, for example, the liver paren- chyma (mean SUV 2.0 – 3.0, maximum SUV 3.0 – 4.0). However, criteria for visual

2018 Society of Nuclear Medicine and Molecular Imaging

213. Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma

strategies, but an evidence-based approach to followup can be achieved by assessing the timing and location of RCC recurrence in a risk-stratified manner. This updated guideline attempts to provide some clarity and guidance for the practic- ing urologist based on the current literature. Methods A systematic search of the PubMed and MEDLINE data- bases was conducted. The searches were limited to English- language publication. The main search terms used to identify eligible studies from the databases (...) :3316- 22. 67. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649-57. 68. Zigeuner R, Hutterer G, Chromecki T, et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 2010;57:102-9

2018 CPG Infobase

214. Guideline for the management of knee and hip osteoarthritis

of this guideline vi Summary: Plain language 1 Recommendations 4 Strength of recommendations 4 Quality of evidence 4 Algorithm 4 Summary of recommendations 5 Strong recommendations for the intervention 5 Strong recommendations against the intervention 6 Conditional recommendations for the intervention 7 Conditional (neutral) recommendations for the intervention 9 Conditional recommendations against the intervention 11 1. Background 13 1.1 Introduction 13 1.2 Objective 13 1.3 Scope and target population 14 1.4 (...) questions for hip OA 691 Guideline for the management of knee and hip osteoarthritis Second edition Summary: Plain language Osteoarthritis (OA) is a chronic disease and the most common form of chronic arthritis. It is characterised by joint pain, stiffness and swelling, and mainly affects the hands, knees and hips. OA most frequently occurs in people aged >55 years, although younger people can also be affected. Risk factors for OA include joint injury, being overweight or obese, and older age

2018 Clinical Practice Guidelines Portal

215. Testicular Cancer

spermatogenesis. Hum Reprod, 2007. 22: 1042. 59. Kim, W., et al. US MR imaging correlation in pathologic conditions of the scrotum. Radiographics, 2007. 27: 1239. 60. Cassidy, F.H., et al. MR imaging of scrotal tumors and pseudotumors. Radiographics, 2010. 30: 665. 61. Gilligan, T.D., et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol, 2010. 28: 3388. 62. Wanderas, E.H., et al. Trends in incidence (...) ., et al. Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am J Surg Pathol, 2017. 41: e22. 70. Dieckmann, K.P., et al. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol, 1996. 14: 3126. 71. Ruf, C.G., et al. Contralateral biopsies in patients with testicular germ cell tumours: patterns of care in Germany

2018 European Association of Urology

216. Prostate Cancer

, 2014. 23: 1494. 50. Nyame, Y.A., et al. Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol, 2016. 34: 1345. 51. Cui, Z., et al. Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis. Medicine (Baltimore), 2017. 96: e5944. 52. Allen, N.E., et al. Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies. J Natl Cancer Inst, 2016. 108. 53. Lippman, S.M., et al. Effect (...) of malignant tumors. UICC International Union Against Cancer. 8th edn. 2017. 73. Cooperberg, M.R., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol, 2005. 173: 1938. 74. Epstein, J.I., et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol, 2005. 29: 1228

2018 European Association of Urology

217. Non-muscle-invasive Bladder Cancer

of the urinary system: non-invasive urothelial neoplasias. In: WHO classification of classification of tumours of the urinary system and male genital organs., A.F. Sauter G, Amin M, Editors. 2004, IARCC Press: Lyon. 36. Epstein, J.I., et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol, 1998. 22: 1435. 37. Soukup, V., et al (...) of the bladder. Urology, 2005. 66: 90. 40. Lamm, D., et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol, 1998. 4: 130. 41. Witjes, J.A., et al. Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. Urology, 2006. 67: 751. 42. May, M., et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol, 2010. 57: 850. 43. van

2018 European Association of Urology

218. Chronic Pelvic Pain

, 2014. 39: 141. 77. Nazif, O., et al. Neural upregulation in interstitial cystitis. Urology, 2007. 69: 24. 78. Melzack, R., et al. Central neuroplasticity and pathological pain. Ann N Y Acad Sci, 2001. 933: 157. 79. Fulbright, R.K., et al. Functional MR imaging of regional brain activation associated with the affective experience of pain. AJR Am J Roentgenol, 2001. 177: 1205. 80. Rygh, L.J., et al. Cellular memory in spinal nociceptive circuitry. Scand J Psychol, 2002. 43: 153. 81. Grace, V.M (...) Urol, 2011. 186: 540. 120. Song, Y., et al. Prevalence and correlates of painful bladder syndrome symptoms in Fuzhou Chinese women. Neurourol Urodyn, 2009. 28: 22. 121. Koziol, J.A., et al. Discrimination between the ulcerous and the nonulcerous forms of interstitial cystitis by noninvasive findings. J Urol, 1996. 155: 87. 122. Messing, E.M., et al. Interstitial cystitis: early diagnosis, pathology, and treatment. Urology, 1978. 12: 381. 123. Parsons, C. Interstitial cystitis: clinical

2018 European Association of Urology

219. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis Full Text available with Trip Pro

relevant papers using data extraction tables. Only articles in the English language containing information on the safety of biologic therapies were included. Two hundred and eighty-nine articles were finally included in the guideline. The guideline was developed and drafted via a series of telephone conference calls and face-to-face meetings, using the retrieved literature to underpin and facilitate discussions. Due to the breadth of the guideline, designated members of the GWG were divided into sub (...) recommendation as a percentage (e.g. 100% would imply all responses were 10/10). Limitations of this guideline The literature search excluded any articles not available in English language and any non-human studies. In addition, there were a very small number of articles identified through the search strategy that we were unable to obtain through university library channels. Plan for review In line with BSR’s guideline protocol, this guideline will be updated in 3–4 years, but if there is a significant

2018 British Society for Rheumatology

220. Optimal Care Pathway for Aboriginal and Torres Strait Islander people with cancer

. • Care coordination for each person should be informed by factors such as gender, kinship, family ties, language barriers and socio-economic issues. – Offer an option to see a health professional of the same gender as the patient, referral to an alternative service provider if this is not possible, or the option of having a support person present. – Acknowledge that family may include people who are not genetically related. • When discussing family history and genetic testing, understand (...) Australians to be diagnosed when cancer is at an advanced stage of disease (Diaz et al. 2015) and are less likely to be hospitalised for cancer care (Australian Institute of Health and Welfare 2015). Aboriginal and Torres Strait Islander people may have poor access to healthcare services due to financial, language, cultural or geographical barriers (Australian Institute of Health and Welfare & Cancer Australia 2013). These disparities in cancer outcomes and overall poorer survival are significantly

2018 Cancer Australia


Guidelines – filter by country